Telodendrimer-based nanocarriers for the treatment of ovarian cancer
Related Experiment Video
Updated: May 7, 2026

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
Published on: March 25, 2019
Kai Xiao1, Nell Suby, Yuanpei Li
1Department of Biochemistry & Molecular Medicine, UC Davis Cancer Center, University of California Davis, Sacramento, CA 95817, USA.
Abstract:
PEG-dendritic block copolymer (telodendrimer) is a unique class of polymers with well-defined structures and tunable aggregation properties, which have been recently developed as novel micelle-based nanocarriers. This new class of nanocarrier is highly versatile, robust, multifunctional and has many unique properties for drug delivery that are superior to most other nanocarriers reported in the literature. Reversible crosslinking of micelles is able to minimize the premature drug release during circulation. These crosslinks can be reversed with endogenous and/or exogenous stimuli. To further facilitate the precise delivery of nanoparticle drugs to cancer cells, the nanoparticles surface can be decorated with ovarian cancer targeting ligands. This review is focused on the various strategies used for the design, preparation, pharmacokinetic, biodistribution and preclinical therapeutic applications of telodendrimer-based nanocarriers for drug delivery in the treatment of ovarian cancer. Lastly, future perspectives for the development of ovarian cancer-targeting telodendrimer nanotherapeutics are also explored.
More Related Videos
09:02Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
Published on: September 27, 2024
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Related Concept Videos
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Targeted Cancer Therapies
There are several types of targeted therapies against...